Literature DB >> 26159051

Autocrine amplification of immature myeloid cells by IL-6 in multiple myeloma-infiltrated bone marrow.

T Matthes1, B Manfroi2, A Zeller3, I Dunand-Sauthier3, B Bogen4, B Huard1,2,3.   

Abstract

Multiple myeloma (MM) invariably develops in the bone marrow (BM), indicating the strong requirement of this tumor for the peculiar BM microenvironment, rich in cytokine and hematopoietic precursor cells. Interleukin-6 (IL-6) and a proliferation inducing ligand (APRIL) are key cytokines implicated in MM development. Here, we show that MM cells changed the hematopoietic microenvironment early upon BM infiltration by strongly downregulating hematopoietic precursor cells from all lineages except myeloid precursor cells. Myeloid precursor cells constituted a major source of APRIL in MM-infiltrated BM, and their proliferative response to IL-6 upregulation explained their relative resistance to MM infiltration. The osteolytic molecule receptor activator of NF-kB ligand (RANK-L) expressed by MM cells started this myeloid proliferation by inducing in a contact-dependent manner IL-6 production by myeloid precursor cells themselves. Taken together, our data demonstrate that MM cells do not simply displace hematopoietic cells upon BM infiltration, but rather selectively modulate the BM microenvironment to preserve a pool of high APRIL-producing myeloid precursor cells. Our data also identify a positive regulation of APRIL by IL-6 in myeloid precursor cells.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26159051     DOI: 10.1038/leu.2015.145

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  35 in total

1.  In vivo interleukin 6 gene expression in the tumoral environment in multiple myeloma.

Authors:  M Portier; G Rajzbaum; X G Zhang; M Attal; C Rusalen; J Wijdenes; P Mannoni; D Maraninchi; M Piechaczyk; R Bataille
Journal:  Eur J Immunol       Date:  1991-07       Impact factor: 5.532

2.  Murine leukocytes with ring-shaped nuclei include granulocytes, monocytes, and their precursors.

Authors:  H Biermann; B Pietz; R Dreier; K W Schmid; C Sorg; C Sunderkötter
Journal:  J Leukoc Biol       Date:  1999-02       Impact factor: 4.962

3.  TRANCE, a TNF family member, is differentially expressed on T cell subsets and induces cytokine production in dendritic cells.

Authors:  R Josien; B R Wong; H L Li; R M Steinman; Y Choi
Journal:  J Immunol       Date:  1999-03-01       Impact factor: 5.422

4.  Human myeloma cells promote the production of interleukin 6 by primary human osteoblasts.

Authors:  A Karadag; B O Oyajobi; J F Apperley; R G Russell; P I Croucher
Journal:  Br J Haematol       Date:  2000-02       Impact factor: 6.998

5.  Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose-escalating study.

Authors:  H C van Zaanen; H M Lokhorst; L A Aarden; H J Rensink; S O Warnaar; J van der Lelie; M H van Oers
Journal:  Br J Haematol       Date:  1998-08       Impact factor: 6.998

6.  Myeloma cells can directly contribute to the pool of RANKL in bone bypassing the classic stromal and osteoblast pathway of osteoclast stimulation.

Authors:  F P L Lai; M Cole-Sinclair; W-J Cheng; J M W Quinn; M T Gillespie; J W Sentry; H-G Schneider
Journal:  Br J Haematol       Date:  2004-07       Impact factor: 6.998

7.  Extralymphatic tumors prepare draining lymph nodes to invasion via a T-cell cross-tolerance process.

Authors:  Olivier Preynat-Seauve; Emmanuel Contassot; Prisca Schuler; Vincent Piguet; Lars E French; Bertrand Huard
Journal:  Cancer Res       Date:  2007-05-15       Impact factor: 12.701

8.  Basic fibroblast growth factor mediates its effects on committed myeloid progenitors by direct action and has no effect on hematopoietic stem cells.

Authors:  A C Berardi; A Wang; J Abraham; D T Scadden
Journal:  Blood       Date:  1995-09-15       Impact factor: 22.113

9.  Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kappaB (RANK) receptors.

Authors:  F Arai; T Miyamoto; O Ohneda; T Inada; T Sudo; K Brasel; T Miyata; D M Anderson; T Suda
Journal:  J Exp Med       Date:  1999-12-20       Impact factor: 14.307

10.  A novel mouse model for multiple myeloma (MOPC315.BM) that allows noninvasive spatiotemporal detection of osteolytic disease.

Authors:  Peter O Hofgaard; Henriette C Jodal; Kurt Bommert; Bertrand Huard; Jo Caers; Harald Carlsen; Rolf Schwarzer; Nicole Schünemann; Franziska Jundt; Mona M Lindeberg; Bjarne Bogen
Journal:  PLoS One       Date:  2012-12-20       Impact factor: 3.240

View more
  11 in total

Review 1.  Epigenetic mechanisms of cell adhesion-mediated drug resistance in multiple myeloma.

Authors:  Yusuke Furukawa; Jiro Kikuchi
Journal:  Int J Hematol       Date:  2016-07-13       Impact factor: 2.490

2.  Osteoclasts promote immune suppressive microenvironment in multiple myeloma: therapeutic implication.

Authors:  Gang An; Chirag Acharya; Xiaoyan Feng; Kenneth Wen; Mike Zhong; Li Zhang; Nikhil C Munshi; Lugui Qiu; Yu-Tzu Tai; Kenneth C Anderson
Journal:  Blood       Date:  2016-07-14       Impact factor: 22.113

3.  Interleukin-6 levels predict event-free survival in pediatric AML and suggest a mechanism of chemotherapy resistance.

Authors:  Alexandra M Stevens; Jennifer M Miller; Jaime O Munoz; Amos S Gaikwad; Michele S Redell
Journal:  Blood Adv       Date:  2017-08-01

4.  IL-6 augments IL-4-induced polarization of primary human macrophages through synergy of STAT3, STAT6 and BATF transcription factors.

Authors:  Sahil Gupta; Arpit Jain; Shahzad Nawaz Syed; Ryan G Snodgrass; Beatrice Pflüger-Müller; Matthias S Leisegang; Andreas Weigert; Ralf P Brandes; Ingo Ebersberger; Bernhard Brüne; Dmitry Namgaladze
Journal:  Oncoimmunology       Date:  2018-07-30       Impact factor: 8.110

5.  APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment.

Authors:  Yu-Tzu Tai; Chirag Acharya; Gang An; Michele Moschetta; Mike Y Zhong; Xiaoyan Feng; Michele Cea; Antonia Cagnetta; Kenneth Wen; Hans van Eenennaam; Andrea van Elsas; Lugui Qiu; Paul Richardson; Nikhil Munshi; Kenneth C Anderson
Journal:  Blood       Date:  2016-04-28       Impact factor: 22.113

Review 6.  Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies.

Authors:  Camille Guillerey; Kyohei Nakamura; Slavica Vuckovic; Geoffrey R Hill; Mark J Smyth
Journal:  Cell Mol Life Sci       Date:  2016-01-22       Impact factor: 9.261

7.  The Low Expression of IL-37 Involved in Multiple Myeloma - Associated Angiogenesis.

Authors:  Zun-Chang Li; Ming-Dong Sun; Yong-Qing Zheng; Hong-Jie Fu
Journal:  Med Sci Monit       Date:  2016-11-03

8.  Granulocytic myeloid-derived suppressor cells promote angiogenesis in the context of multiple myeloma.

Authors:  Marilène Binsfeld; Joséphine Muller; Virginie Lamour; Kim De Veirman; Hendrik De Raeve; Akeila Bellahcène; Els Van Valckenborgh; Frédéric Baron; Yves Beguin; Jo Caers; Roy Heusschen
Journal:  Oncotarget       Date:  2016-06-21

Review 9.  NRF2 Is One of the Players Involved in Bone Marrow Mediated Drug Resistance in Multiple Myeloma.

Authors:  Chia-Hung Yen; Hui-Hua Hsiao
Journal:  Int J Mol Sci       Date:  2018-11-07       Impact factor: 5.923

10.  Bioactive Compounds from Abelmoschus manihot L. Alleviate the Progression of Multiple Myeloma in Mouse Model and Improve Bone Marrow Microenvironment.

Authors:  Jianhao Hou; Jinjun Qian; Zhenlin Li; Aixiu Gong; Sixia Zhong; Li Qiao; Shihui Qian; Yanxin Zhang; Renjie Dou; Rui Li; Ye Yang; Chunyan Gu
Journal:  Onco Targets Ther       Date:  2020-01-31       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.